Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
MyndTec, Inc. ( (TSE:MYTC) ) has shared an announcement.
MyndTec Inc. has completed a tenth tranche of its non-brokered private placement, issuing 618,118 units at $0.20 per unit for gross proceeds of $123,623.60, bringing total funds raised under the offering to $1,067,493.40 through 5,337,323 units. Each unit consists of one common share and a half warrant, with whole warrants exercisable at $0.24 for 36 months, and the proceeds earmarked for working capital, corporate development, machine learning model development, debt settlement, investor relations and marketing, subject to statutory hold periods, U.S. securities transfer restrictions and final acceptance by the Canadian Securities Exchange. Certain related parties participated in the financing under exemptions from formal valuation and minority approval rules, underscoring insider support while highlighting the company’s continued reliance on equity financing to fund operations and technology development in a tightly regulated capital markets environment.
The most recent analyst rating on (TSE:MYTC) stock is a Hold with a C$0.02 price target. To see the full list of analyst forecasts on MyndTec, Inc. stock, see the TSE:MYTC Stock Forecast page.
Spark’s Take on TSE:MYTC Stock
According to Spark, TipRanks’ AI Analyst, TSE:MYTC is a Neutral.
The score is driven primarily by very weak financial performance (shrinking revenue, persistent losses, negative equity, and ongoing cash burn) and bearish technical signals (price below key moving averages with negative MACD). Recent financing provides some near-term support but also underscores continued funding dependence.
To see Spark’s full report on TSE:MYTC stock, click here.
More about MyndTec, Inc.
MyndTec Inc. is a CSE-listed medical technology company specializing in neurological treatment and rehabilitation. The company focuses on neurostimulation-based therapies to restore function in patients with central nervous system diseases and injuries, including Parkinson’s disease, Alzheimer’s disease and stroke. Its flagship product, the MyndMove system, is a non-invasive functional electrical stimulation intervention that leverages neuroplasticity to help patients re-establish voluntary movement and improve independence, while the company continues researching new neurostimulation applications to enhance patient outcomes.
Average Trading Volume: 23,961
Technical Sentiment Signal: Sell
See more insights into MYTC stock on TipRanks’ Stock Analysis page.